The NeuroNEXT Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) study of Spinal Muscular Atrophy (SMA) Biomarkers in the Immediate Postnatal Period of Development is still recruiting both infants with no medical condition as well as infants with SMA between 0-6 months of age at the time of enrollment.
They have been recruiting infants for their study since January with the following video:
Let's help them spread the word!
Let's help them spread the word!
Comments
Post a Comment